Clinical Trial Update: Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE) [Phase 2]

View source ↗

Summary

Phase 2 study investigating pimavanserin for agitation and aggression in Alzheimer's disease; the trial was terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Pimavanserin (pimavanserin)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Agitation and Aggression in Alzheimer's Disease | Phase 2 | Status: TERMINATED | Results posted: 2019-03-28